Luxturna serves as a model for other gene therapy candidates

Just published…This first FDA-approved gene therapy for a hereditary genetic disease, marks a new cycle of therapeutic innovation, especially for inherited retinal disease & potentially for common disorders, such as AMD & diabetic retinopathy.

Voretigene neparvovec-rzyl for treatment of RPE65-mediated inherited retinal diseases: a model for ocular gene therapy development